Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

NCT07197866 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D LLC as lead sponsor.

NCT NCT07197866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07197866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2025
Completion date
May 17, 2029
Enrollment
200 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy